Silence Therapeutics plc Business Development
Silence Therapeutics plc (SLN) reported Business Development of $4.75 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:BusinessDevelopment · last filed 2026-08-10
- Silence Therapeutics plc business development for the quarter ending 2026-06-30 was $4.75M, a 61.16% decline year-over-year.
- Silence Therapeutics plc business development for the quarter ending 2026-03-31 was $4.34M, a 70.40% decline year-over-year.
- Silence Therapeutics plc business development for the quarter ending 2025-12-31 was $4.82M, a 68.26% decline year-over-year.
- Silence Therapeutics plc business development for the quarter ending 2025-09-30 was $13.15M, a 3.62% decline year-over-year.
- Silence Therapeutics plc business development for fiscal 2025 was $44.87M, a 4.59% increase from fiscal 2024.
- Silence Therapeutics plc business development for fiscal 2024 was $42.90M, a 22.41% increase from fiscal 2023.
- Silence Therapeutics plc business development for fiscal 2023 was $35.05M, a 44.10% increase from fiscal 2022.
- Silence Therapeutics plc business development for fiscal 2022 was $24.32M.
| Period end | Business Development 3 month | Business Development 6 month | Business Development 9 month | Business Development 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.75M 10-Q · filed 2026-08-10 | $9.09M 10-Q · filed 2026-08-10 | $13.91M derived: sum of 3 quarters · filed 2026-08-10 | $27.06M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $4.34M 10-Q · filed 2026-05-07 | $9.16M derived: sum of 2 quarters · filed 2026-05-07 | $22.31M derived: sum of 3 quarters · filed 2026-05-07 | $34.54M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $4.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $17.97M derived: sum of 2 quarters · filed 2026-03-05 | $30.20M derived: sum of 3 quarters · filed 2026-08-10 | $44.87M 10-K · filed 2026-03-05 |
| 2025-09-30 | $13.15M 10-Q · filed 2025-11-06 | $25.38M derived: sum of 2 quarters · filed 2026-08-10 | $40.05M 10-Q · filed 2025-11-06 | $55.24M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $12.23M 10-Q · filed 2026-08-10 | $26.91M 10-Q · filed 2026-08-10 | $42.09M derived: sum of 3 quarters · filed 2026-08-10 | $55.73M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $14.67M 10-Q · filed 2026-05-07 | $29.86M derived: sum of 2 quarters · filed 2026-05-07 | $43.50M derived: sum of 3 quarters · filed 2026-05-07 | $51.27M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $15.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $28.83M derived: sum of 2 quarters · filed 2026-03-05 | $36.60M derived: sum of 3 quarters · filed 2026-03-05 | $42.90M 10-K · filed 2026-03-05 |
| 2024-09-30 | $13.64M 10-Q · filed 2025-11-06 | $21.41M derived: sum of 2 quarters · filed 2025-11-06 | $27.71M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $7.77M 10-Q · filed 2025-08-07 | $14.07M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $6.30M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $35.05M 10-K · filed 2025-02-27 | |||
| 2022-12-31 | $24.32M 10-K · filed 2025-02-27 |